In patients with oral cavity cancers, hypermethylation of DAPK, TAC1, GALR1, NPY1R, SSTR1, and VEGFR3 was associated with significantly reduced survival, with hazard ratios of 2.93 (95% CI: 1.17–7.35), 4.29 (95% CI: 1.54–11.9), 2.44 (95% CI: 1.00–5.96), 2.37 (95% CI: 1.05–5.34), 5.38 (95% CI: 1.19–24.3), and 2.55 (95% CI: 1.12–5.78), respectively (Figure 3C). This evidence concerns the gene TAC1 and oral cavity cancer.